165 related articles for article (PubMed ID: 31111641)
41. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
42. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
Fakheri H; Taghvaei T; Hosseini V; Bari Z
Helicobacter; 2012 Feb; 17(1):43-8. PubMed ID: 22221615
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy.
Zhang F; Bao ZJ; Shi DM; Xiang P; Xiao L; Huang YQ; Zhang GS; Yin SM
Braz J Med Biol Res; 2016 Feb; 49(2):e5080. PubMed ID: 26871968
[TBL] [Abstract][Full Text] [Related]
44. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies.
Wong WM; Wong BC; Lu H; Gu Q; Yin Y; Wang WH; Fung FM; Lai KC; Xia HH; Xiao SD; Lam SK
Aliment Pharmacol Ther; 2002 Apr; 16(4):793-8. PubMed ID: 11929398
[TBL] [Abstract][Full Text] [Related]
45. Eradication of Helicobacter pylori: recent advances in treatment.
McLoughlin RM; O'Morain CA; O'Connor HJ
Fundam Clin Pharmacol; 2005 Aug; 19(4):421-7. PubMed ID: 16011728
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
[TBL] [Abstract][Full Text] [Related]
47. Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?
Lv ZF; Wang FC; Zheng HL; Wang B; Xie Y; Zhou XJ; Lv NH
World J Gastroenterol; 2015 Feb; 21(8):2522-33. PubMed ID: 25741163
[TBL] [Abstract][Full Text] [Related]
48. [Jinghuaweikang capsules combined with furazolidone-based triple or quadruple therapy as the rescue treatment for Helicobacter pylori infection: a multicenter randomized controlled clinical trial].
Cheng H; Hu FL; Sheng JQ; An HJ; Xu L; Liu FX; Li Y; Hao Q; Zheng PY; Lu GF; Cao ZQ; Wang YP
Zhonghua Yi Xue Za Zhi; 2016 Nov; 96(40):3206-3212. PubMed ID: 27852385
[No Abstract] [Full Text] [Related]
49. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
[TBL] [Abstract][Full Text] [Related]
50. Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease.
Khatibian M; Ajvadi Y; Nasseri-Moghaddam S; Ebrahimi-Dariani N; Vahedi H; Zendehdel N; Sotoudehmanesh R; Agah S; Mikaeli J; Pourshams A; Ali-Asgari A; Malekzadeh R; Massarrat S
Arch Iran Med; 2007 Apr; 10(2):161-7. PubMed ID: 17367217
[TBL] [Abstract][Full Text] [Related]
51. Second-line rescue treatment of
Lin TF; Hsu PI
World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial.
Munteanu D; Etzion O; Ben-Yakov G; Halperin D; Eidelman L; Schwartz D; Novack V; Abufreha N; Krugliak P; Rozenthal A; Gaspar N; Moshkalo A; Dizingof V; Fich A
PLoS One; 2017; 12(9):e0183302. PubMed ID: 28957341
[TBL] [Abstract][Full Text] [Related]
53. Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.
Felga GE; Silva FM; Barbuti RC; Navarro-Rodriguez T; Zaterka S; Eisig JN
World J Gastroenterol; 2008 Oct; 14(40):6224-7. PubMed ID: 18985815
[TBL] [Abstract][Full Text] [Related]
54. [Influence of different timing of
He CX; Kong FT; Liang F; Wang KX; Li H; Liu YL; Zhao W; Zhou PP; Kong FL
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(22):1731-1734. PubMed ID: 31216821
[No Abstract] [Full Text] [Related]
55. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.
Mansour-Ghanaei F; Joukar F; Naghipour MR; Forouhari A; Saadat SM
World J Gastroenterol; 2015 Jan; 21(2):661-6. PubMed ID: 25593496
[TBL] [Abstract][Full Text] [Related]
56. A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine.
Liu WZ; Xiao SD; Hu PJ; Lu H; Cui Y; Tytgat GN
Aliment Pharmacol Ther; 2000 Nov; 14(11):1519-22. PubMed ID: 11069324
[TBL] [Abstract][Full Text] [Related]
57. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
58. [New ultrashort scheme for helicobacter pylori infection eradication using tetracyline, furazolidone and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia].
Araujo Castillo R; Pinto Valdivia JL; Ramírez D; Cok García J; Bussalleu Rivera A
Rev Gastroenterol Peru; 2005; 25(1):23-41. PubMed ID: 15818420
[TBL] [Abstract][Full Text] [Related]
59. Eradication rates in Italian subjects heterogeneously managed for Helicobacter pylori infection. Time to abandon empiric treatments in Southern Europe.
Di Ciaula A; Scaccianoce G; Venerito M; Zullo A; Bonfrate L; Rokkas T; Portincasa P
J Gastrointestin Liver Dis; 2017 Jun; 26(2):129-137. PubMed ID: 28617882
[TBL] [Abstract][Full Text] [Related]
60. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Lu B; Wang J; Li J; Liu L; Chen Y
Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
